Research progress in dependence potential evaluation of antidepressants of biogenic amines

doi:10.19803/j.1672-8629.2022.01.26

Abstract

Abstract: Antidepressants of biogenic amines promised good economic benefits and prospects of development. In recent years, the research and development of antidepressants targeting the reuptake inhibitory effect of the 5-HT/NE/DA triple targets has been accelerated. However, abuse and addiction as possible side effects have become a public health concern globally. Drug dependence evaluation guidelines issued by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and China's National Medical Products Administration (NMPA) all require non-clinical dependence potential evaluation of such drugs for the purpose of evaluating the dependence potential of these drugs effectively and guide clinical use. Through literature research, the status quo, existing problems and prospects of research on antidepressants of biogenic amines and evaluation of their dependence potential were studied. It is recommended that China learn from the experience of FDA and EMA to step up investment in the non-clinical dependence evaluation platform of antidepressants of biogenic amines and update related policies and regulations.

Key words: biogenic amines, antidepressant, dependence potential evaluation

CLC Number:

R964

CHEN Ying, LI Liang, JI Wenyue, Wu Chunqi, Dong Yansheng. Research progress in dependence potential evaluation of antidepressants of biogenic amines[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 113-116.

References

[1] LI BJ, FRISTON K, MODY M, et al.A brain network model for depression: from symptom understanding to disease intervention[J]. CNS Neurosci Ther, 2018, 24(11): 1004-1019.
[2] SILVERBERG ND, PANENKA WJ.Antidepressants for depression after concussion and traumatic brain injury are still best practice[J]. BMC Psychiatry, 2019, 19(1): 100-103.
[3] BEYER C, CAPPETTA K, JOHNSON JA, et al.Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants[J]. Depress Anxiety, 2017, 34(12): 1134-1146.
[4] BLIER P.Neurotransmitter targeting in the treatment of depression[J]. J Clin Psychiatry, 2013, 74(2): 19-24.
[5] HÖFLICH A, MICHENTHALER P, KASPER S, et al. Circuit mechanisms of reward, anhedonia, and depression[J]. Int J Neuropsychopharmacol, 2019, 22(2): 105-118.
[6] PECIÑA M, SIKORA M, AVERY ET, et al. Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response[J]. Eur Neuropsychopharmacol, 2017, 27(10): 977-986.
[7] ROTOLO RA, PRESBY RE, TRACY O, et al.The novel atypical dopamine transport inhibitor CT-005404 has pro-motivational effects in neurochemical and inflammatory models of effort-based dysfunctions related to psychopathology[J]. Neuropharmacology. 2020, 18: 108325.
[8] ZHAN P, WANG XS, LIU XY.Contemporary molecular targeted drug in the context of“precision medicine”: an attempting discussion of “precision drug design”[J]. Progress in Chemistry(化学进展), 2016, 9: 1363-1386.
[9] DELGADO PL.Depression: the case for a monoamine deficiency[J]. J Clin Psychiatry, 2000, 61(6): 7-11.
[10] HILLHOUSE TM, PORTER JH.A brief history of the development of antidepressant drugs: from mono-amines to glutamate[J]. Exp Clin Psychopharmacol, 2015, 23(1): 1-21.
[11] BUNNEY WE JR, DAVIS JM.Norepinephrine in depressive reactions[J]. Arch Gen Psychiatry, 1965, 13(6): 483-494.
[12] GRZELCZYK J, BUDRYN G, PEÑA-GARCÍA J, et al. Evaluation of the inhibition of monoamine oxidase a by bioactive coffee compounds protecting serotonin degradation[J]. Food Chem, 2021, 348: 129108-129119.
[13] MONCHAUX DE OC, POURTAU L, VANCASSEL S, et al.Saffron extract-Induced improvement of depressive-like behavior in mice is associated with modulation of monoaminergic neurotransmission[J]. Nutrients, 2021, 13(3): 904-920.
[14] LAUGHREN TP, GOBBURU J, TEMPLE RJ, et al.Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant[J]. J Clin Psychiatry, 2011, 72(9): 1166-1173.
[15] EL MANSARI M, CRNIC A, OOSTERHOF C, et al.Long-term administration of the antidepressant vilazodone modulates rat brain monoaminergic systems[J]. Neuropharmacology, 2015, 99: 696-704.
[16] LIM LW, JANSSEN ML, KOCABICAK E, et al.The antidepressant effects of ventromedial prefrontal cortex stimulation is associated with neural activation in the medial part of the subthalamic nucleus[J]. Behav Brain Res, 2015, 279: 17-21.
[17] EL-MARASY SA, ELAWDAN SA, HASSAN A, et al.Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: behavioral, biochemical, molecular and immunohistochemical evidence[J]. Chem Biol Interact, 2021, 334: 109329.
[18] QIAO YL, ZHOU JJ, LIANG JH, et al.Uncaria rhynchophylla ameliorates unpredictable chronic mild stress-induced depression in mice via activating 5-HT1A receptor: insights from transcriptomics[J]. Phytomedicine, 2021, 81: 153436.
[19] CANALE V, KOTAŃSKA M, DZIUBINA A, et al. Design, sustainable synthesis and biological evaluation of a novel dual α2A/5-HT7 receptor antagonist with antidepressant-like properties[J]. Molecules, 2021, 26(13): 3828.
[20] FOX ME, LOBO MK.The molecular and cellular mechanisms of depression: a focus on reward circuitry[J]. Mol Psychiatry, 2019, 24(12): 1798-1815.
[21] ENGELHARD B, FINKELSTEIN J, COX J, et al.Specialized coding of sensory, motor and cognitive variables in VTA dopamine neurons[J]. Nature, 2019, 570: 509-513.
[22] MUNZAR P, LAUFERT MD, KUTKAT SW, et al.Effects of various serotonin agonist, antagonist, and uptake inhibitors on the discrimininative stimulus effects of methamphetamine in rats[J]. J Pharmacol Exp Ther, 1999, 291(1): 239-250.
[23] SUBHAN F, DESLANDES PN, PACHE DM, et al.Do antidepre-ssants affect motivation in conditioned place preference?[J]. European Journal of Pharmacology, 2000, 408(3): 257-263.
[24] RECINELLA L, CHIAVAROLI A, FERRANTE C, et al.Effects of central RVD-hemopressin(α) administration on anxiety, feeding behavior and hypothalamic neuromodulators in the rat[J]. Pharmacol Rep, 2018, 70(4): 650-657.
[25] OSSEWAARDE L, VERKES R, HERMANS E, et al.Two-week administration of the combined serotonin-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits[J]. Biol Psychiatry, 2011, 70(6): 568-574.
[26] ZHANG Y, CUI XL, YANG P.Adverse drug reaction induced by antidepressants of SSRI and SNRI[J]. Chinese Journal of pharmacovigilance(中国药物警戒), 2010, 7(9): 554-556.
[27] CALDARONE BJ, PATERSON NE, ZHOU J, et al.The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties[J]. The Journal of Pharmacology and Experimental Therapeutics, 2010, 335(3): 762-770.
[28] SØRENSEN G, HUSUM H, BRENNUM LT, et al. Addiction-related effects of DOV 216,303 and cocaine: a comparative study in the mouse[J]. Basic & Clinical Pharmacology & Toxicology, 2014, 114(6): 451-459.
[29] National Medical Products Administration. Guideline on the non-clinical investigation of the dependence potential of drugs[S].National Medical Products Administration, 2007.
[30] Food and Drug Administration. Guidance for industry: assessment of abuse potential of drugs[S]. Food and Drug Administration, 2017.
[31] European Medicines Agency.Guideline on the non-clinical investigation of the dependence potential of medicinal products[S]. European Medicines Agency, 2006.
[32] ABBRUSCATO TJ, TRIPPIER PC.DARK classics in chemical neuroscience: methamphetamine[J]. ACS Chem Neurosci, 2018, 9(10): 2373-2378.